Shelter Pharma FY26 presentation: revenue up 44%, targets 200 Cr by 2030
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shelter Pharma submitted its investor presentation for H2 and FY26. Revenue grew 44.35% YoY to 73.13 Cr (from 50.66 Cr in FY25). PAT rose 24.72% to 9.03 Cr. EBITDA margin declined to 17.39% from 19.88%. ROCE 3-year average is 25.74 percent and ROE is 19.39 percent. Company is almost debt-free. Management outlined Vision 2030 targeting 200 Cr annual revenue by 2030, with a new manufacturing facility coming up near Himmatnagar, Gujarat. 3-year revenue CAGR stands at 26 percent and PAT CAGR at 15 percent.
Strong revenue growth but EBITDA margin is compressing. Vision 2030 target and new capacity signal long-term growth ambition.